Serum neurofilament light chain as a potential biomarker in restless legs syndrome: a cross-sectional study
Yazarlar (5)
Dr. Öğr. Üyesi Aysu YETİŞ
Kırşehir Ahi Evran Üniversitesi, Türkiye
Kırşehir Ahi Evran Üniversitesi, Türkiye
Doç. Dr. Bilal İLANBEY
Kırşehir Ahi Evran Üniversitesi, Türkiye
Bandırma Onyedi Eylül University, Türkiye
Dr. Öğr. Üyesi Selcen DURAN
Kırşehir Ahi Evran Üniversitesi, Türkiye
| Makale Türü | Özgün Makale |
| Makale Alt Türü | SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale |
| Dergi Adı | Neurological Research |
| Dergi ISSN | 0161-6412 Wos Dergi Scopus Dergi |
| Dergi Tarandığı Indeksler | SCI-Expanded |
| Dergi Grubu | Q4 |
| Makale Dili | Türkçe |
| Basım Tarihi | 02-2025 |
| Cilt No | 47 |
| Sayı | 4 |
| Sayfalar | 284 / 289 |
| DOI Numarası | 10.1080/01616412.2025.2472836 |
| Makale Linki | https://doi.org/10.1080/01616412.2025.2472836 |
| Özet |
| Objective: Neurofilament light chain (NfL) has emerged as a promising biomarker for several neurological diseases. Therefore, we investigated its serum levels and their association with disease characteristics, including duration, severity, and medication use in patients with restless legs syndrome (RLS). Method: This cross-sectional prospective study included 71 RLS patients and 70 healthy controls. RLS patients were characterized based on disease duration, severity, and medication use. NfL levels were quantified using commercial enzyme-linked immunosorbent assay kits. Result: No significant differences in NfL levels were observed between RLS patients and controls (p > 0.05). Furthermore, the levels were not significantly associated with disease duration or severity in RLS patients (p > 0.05). Conclusion: These findings do not support the use of NfL as a biomarker for RLS. Further large-scale studies are needed to evaluate its role in RLS. |
| Anahtar Kelimeler |
| biomarker | neurodegeneration | Neurofilament light chain | restless legs syndrome | Willis–Ekbom disease |
BM Sürdürülebilir Kalkınma Amaçları
| Atıf Sayıları | |
| WoS | 2 |
| SCOPUS | 1 |